Patents by Inventor Neil Berinstein

Neil Berinstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING DIFFUSE LARGE B-CELL LYMPHOMA
    Publication number: 20230381309
    Abstract: The present application relates generally to methods for treating hematologic malignancy such as diffuse large B cell lymphoma (DLBCL), and in particular to methods involving detecting the expression of Programmed Death-Ligand 1 (PD-L1) in a biological sample of the subject and administering a T cell activation therapeutic with an inhibitor of PD-L1 or Programmed Death 1 (PD-1). It was surprisingly found that the level of PD-L1 expression correlates with the clinical responses with the T cell activation therapeutic together with an inhibitor of PD-L1 or PD-1 in the treatment of hematologic malignancies, thus, making PD-L1 an unexpected biomarker for the treatment of DLBCL.
    Type: Application
    Filed: October 13, 2021
    Publication date: November 30, 2023
    Inventors: Stephan FISET, Yogesh BRAMHECHA, Rebekah CONLON, Neil BERINSTEIN
  • Vaccines Using High-Dose Cytokines
    Publication number: 20160151473
    Abstract: The present invention relates to the field of cancer immunotherapy. In particular, vaccines are administered in conjunction with high doses of cytokines to enhance an anti-tumor immune response.
    Type: Application
    Filed: January 29, 2016
    Publication date: June 2, 2016
    Inventors: David E. Spaner, Neil Berinstein, Mark DeBenedette, Igor Astasturov, Teresa Petrella, Umit Bagriacik, Gail Lumber, Neill Iscoe, Caitlin Hammond, Paul Hamilton
  • Method of Inducing And/Or Enhancing An Immune Response to Tumor Antigens
    Publication number: 20150352198
    Abstract: An improved method of inducing and/or enhancing an immune response to a tumor antigen is disclosed. The method involves administering the tumor antigen, nucleic acid coding therefor, vectors and/or cells comprising said nucleic acid, or vaccines comprising the aforementioned to a lymphatic site.
    Type: Application
    Filed: March 4, 2015
    Publication date: December 10, 2015
    Applicant: SANOFI PASTEUR LIMITED
    Inventors: Neil Berinstein, James Tartaglia, Phillipe Moingeon, Brian Barber
  • Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer
    Patent number: 8946174
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: February 3, 2015
    Assignee: Sanofi Pasteur Limited
    Inventors: Neil Berinstein, Corey Lovitt, Mark Parrington, Artur Pedyczak, Laszlo Radvanyi, Scott Gallichan, Devender Singh-Sandhu, Raymond P. Oomen, Shi-Xian Cao
  • Multi-antigen vectors of melanoma
    Patent number: 8911991
    Abstract: The present invention relates to peptides, polypeptides, and nucleic acids and the use of the peptide, polypeptide or nucleic acid in preventing and/or treating cancer. In particular, the invention relates to peptides and nucleic acid sequences encoding such peptides for use in diagnosing, treating, or preventing melanoma.
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: December 16, 2014
    Assignee: Sanofi Pasteur Limited
    Inventors: Neil Berinstein, James Tartaglia, Mark Parrington, Dennis L. Panicali, Linda Gritz
  • Monoclonal antibodies and uses thereof
    Patent number: 8802383
    Abstract: The technology relates to monoclonal antibodies useful in the identification of cancer cells. In one embodiment, mAbs with specificity for tumor antigens are provided. In one embodiment, methods for treating cancer using mAbs are provided. In another embodiment, methods for detecting cancerous cells are provided. In another embodiment, kits for detecting cancerous cells are provided.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: August 12, 2014
    Assignee: Sanofi Pasteur Limited
    Inventors: Neil Berinstein, Devender Satsangi Singh Sandhu, Corey Lovitt, Artur Pedyczak, Scott Gallichan, Laszlo Radvanyi
  • Immunogenic Polypeptides Encoded by MAGE Minigenes and Uses Thereof
    Publication number: 20130216563
    Abstract: The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed.
    Type: Application
    Filed: August 1, 2012
    Publication date: August 22, 2013
    Inventors: Neil Berinstein, James Tartaglia, John A. Tine, Philippe Moingeon, Thierry Boon-Falleur, Pierre Vander Bruggen
  • Monoclonal antibodies and uses thereof
    Patent number: 8361706
    Abstract: The technology relates to monoclonal antibodies useful in the identification of cancer cells. In one embodiment, mAbs with specificity for tumor antigens are provided. In one embodiment, methods for treating cancer using mAbs are provided. In another embodiment, methods for detecting cancerous cells are provided. In another embodiment, kits for detecting cancerous cells are provided.
    Type: Grant
    Filed: July 14, 2010
    Date of Patent: January 29, 2013
    Assignee: Sanofi Pasteur Limited
    Inventors: Neil Berinstein, Devender Singh-Sandhu, Corey Lovitt, Artur Pedyczak, Laszlo Radvanyi, Scott Gallichan
  • Tumor Antigens for the Prevention and/or Treatment of Cancer
    Publication number: 20130011422
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Application
    Filed: May 31, 2012
    Publication date: January 10, 2013
    Inventors: Neil Berinstein, Scott Gallichan, Corey Lovitt, Mark Parrington, Laszlo Radvanyi, Devender Singh-Sandhu
  • Monoclonal Antibodies and Uses Thereof
    Publication number: 20120295275
    Abstract: The technology relates to monoclonal antibodies useful in the identification of cancer cells. In one embodiment, mAbs with specificity for tumor antigens are provided. In one embodiment, methods for treating cancer using mAbs are provided. In another embodiment, methods for detecting cancerous cells are provided. In another embodiment, kits for detecting cancerous cells are provided.
    Type: Application
    Filed: May 16, 2012
    Publication date: November 22, 2012
    Applicant: Sanofi Pasteur, Ltd.
    Inventors: Neil Berinstein, Devender Satsangi Singh Sandhu, Corey Lovitt, Artur Pedyczak, Scott Gallichan, Laszlo Radvanyi
  • Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
    Patent number: 8257717
    Abstract: The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: September 4, 2012
    Assignees: Sanofi Pasteur Limited, Ludwig Institute for Cancer Research
    Inventors: Neil Berinstein, James Tartaglia, John A. Tine, Philippe Moingeon, Thierry Boon-Falleur, Pierre Vander Bruggen
  • Tumor antigens for prevention and/or treatment of cancer
    Patent number: 8207314
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Grant
    Filed: April 15, 2004
    Date of Patent: June 26, 2012
    Assignee: Sanofi Pasteur Limited
    Inventors: Neil Berinstein, Scott Gallichan, Corey Lovitt, Mark Parrington, Laszlo Radvanyi, Devender Singh-Sandhu
  • Method of Inducing and/or Enhancing an Immune Response to Tumor Antigens
    Publication number: 20110319480
    Abstract: An improved method of inducing and/or enhancing an immune response to a tumor antigen is disclosed. The method involves administering the tumor antigen. nucleic acid coding therefor, vectors and/or cells comprising said nucleic acid or vaccines comprising the aforementioned to a lymphatic site.
    Type: Application
    Filed: August 2, 2011
    Publication date: December 29, 2011
    Inventors: Neil Berinstein, James Tartaglia, Philippe Moingeon, Brian Barber
  • Tumor Antigens BFA5 for Prevention and/or Treatment of Cancer
    Publication number: 20110311543
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Application
    Filed: August 23, 2011
    Publication date: December 22, 2011
    Inventors: Neil Berinstein, Scott Gallichan, Corey Lovitt, Parrington Mark, Artur Pedyczak, Laszio Radvanyi, Devender Singh-Sandhu
  • Immunogenic Polypeptides Encoded by MAGE Minigenes and Uses Thereof
    Publication number: 20110250234
    Abstract: The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed.
    Type: Application
    Filed: October 27, 2010
    Publication date: October 13, 2011
    Inventors: Neil Berinstein, James Tartaglia, John A. Tine, Philippe Moingeon, Thierry Boon-Falleur, Pierre Vander Bruggen
  • Tumor antigens Bfa5 for prevention and/or treatment of cancer
    Patent number: 8021664
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Grant
    Filed: April 15, 2004
    Date of Patent: September 20, 2011
    Assignee: Sanofi Pasteur Limited
    Inventors: Neil Berinstein, Scott Gallichan, Corey Lovitt, Mark Parrington, Artur Pedyczak, Laszlo Radvanyi, Devender Singh-Sandhu
  • Method of inducing and/or enhancing an immune response to tumor antigens
    Patent number: 8017590
    Abstract: An improved method of inducing and/or enhancing an immune response to a tumor antigen is disclosed. The method involves administering the tumor antigen, nucleic acid coding therefor, vectors and/or cells comprising said nucleic acid, or vaccines comprising the aforementioned to a lymphatic site.
    Type: Grant
    Filed: October 20, 2000
    Date of Patent: September 13, 2011
    Assignee: Sanofi Pasteur Limited
    Inventors: Neil Berinstein, James Tartaglia, Philippe Moingeon, Brian Barber
  • TUMOR ANTIGENS BFA4 AND BCY1 FOR PREVENTION AND / OR TREATMENT OF CANCER
    Publication number: 20110117640
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Application
    Filed: September 23, 2010
    Publication date: May 19, 2011
    Inventors: Neil Berinstein, Corey Lovitt, Mark Parrington, Artur Pedyczak, Laszlo Radvanyi, Scott Gallichan, Devender Singh-Sandhu, Raymond P. Oomen, Shi-Xian Cao
  • Monoclonal Antibodies and Uses Thereof
    Publication number: 20110045502
    Abstract: The technology relates to monoclonal antibodies useful in the identification of cancer cells. In one embodiment, mAbs with specificity for tumor antigens are provided. In one embodiment, methods for treating cancer using mAbs are provided. In another embodiment, methods for detecting cancerous cells are provided. In another embodiment, kits for detecting cancerous cells are provided.
    Type: Application
    Filed: July 14, 2010
    Publication date: February 24, 2011
    Applicant: Sanofi Pasteur, Ltd.
    Inventors: Neil Berinstein, Devender Singh-Sandhu, Corey Lovitt, Artur Pedyczak, Laszlo Radvanyi
  • Tumor antigens BFA4 and BCY1 for prevention and / or treatment of cancer
    Patent number: 7851213
    Abstract: The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: December 14, 2010
    Assignee: Sanofi Pasteur Limited
    Inventors: Neil Berinstein, Corey Lovitt, Mark Parrington, Artur Pedyczak, Laszlo Radvanyi, Scott Gallichan, Devender Singh-Sandhu, Raymond P. Oomen, Shi-Xian Cao